Mingazheva, E.T.,
Prokofyeva, D.S.,
Valova, Ya.V.,
Andreeva, E.A.,
Nurgalieva, A.Kh.,
Valiev, R.R.,
Ekomasova, N.V.,
Faishanova, R.R.,
Romanova, A.R.,
Khusnutdinova, E.K. (2022) for the development and severity of diseases. Our case-control study is aimed at
researching potentially pathogenic
Fedorova, Yu Yu,
Sagitova, A.V.,
Mingazheva, E.T.,
Faishanova, R.R.,
Zagitov, I.R.,
Andreeva, E.A.,
Nurgalieva, A.Kh.,
Khusnutdinova, E.K.,
Darvish, M.,
Prokofyeva, D.S. (2024) researched – 89.91%, despite a good response to primary therapy, had a relapse of the disease after 7 years
Fedorova, Yu. Yu.,
Nurgalieva, A.K.,
Petrova, S.G.,
Murzina, R.R.,
Dzhaubermezov, M.A.,
Ekomasova, N.V.,
Khusnutdinova, E.K.,
Prokofieva, D.S. (2024) in the Republic of Bashkortostan were used as
research material. Genotyping was per-formed using the real-time PCR
Savelieva, O.N.,
Karunas, A.S.,
Biktasheva, A.R.,
Vlasova, A.O.,
Khidiyatova, I.M.,
Etkina, E.I.,
Khusnutdinova, E.K. (2024) reactions. The aim of the
research was to study the role of polymorphic variants of the AOC1, HRH2, HRH3
Mustafin, R.N.,
Bermisheva, M.A.,
Karunas, A.S.,
Akhmetshin, A.A.,
Monakhova, A.S.,
Khusnutdinova, E.K. (2025) described by
researchers from various countries, and 7 pathogenic variants: NM_001042492.3:c.55G>T (NP
Galimova, E.F.,
Gromenko, I.D.,
Gilyazova, I.R.,
Gromenko, D.D.,
Galimov, K.Sh.,
Abdeeva, G.R.,
Gromenko, Yu.Yu.,
Khusnutdinova, E.K.,
Galimov, Sh.N. (2024) % depending on the population studied The
research is aimed to study the possibility of using miR-20a, miR-135